Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates

First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors

(2017) Geoffrey I. Shapiro et al.   INVESTIGATIONAL NEW DRUGS

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer

(2016) J. F. Liu et al.   ANNALS OF ONCOLOGY

Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma

(2016) Jamie E. Flerlage et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Preclinical Efficacy of the Auristatin-Based Antibody–Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors

(2016) Anette Sommer et al.   CANCER RESEARCH

Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models

(2016) P. M. Challita-Eid et al.   CANCER RESEARCH

ABBV-399, a c-Met Antibody–Drug Conjugate that Targets Both MET –Amplified and c-Met–Overexpressing Tumors, Irrespective of MET Pathway Dependence

(2016) Jieyi Wang et al.   CLINICAL CANCER RESEARCH

New developments for antibody-drug conjugate-based therapeutic approaches

(2016) Bart ECG de Goeij et al.   CURRENT OPINION IN IMMUNOLOGY

Depatuxizumab mafodotin. Anti-EGFR antibody-drug conjugate, Treatment of glioblastoma multiforme

(2016) Z. Gajdosik   DRUGS OF THE FUTURE

A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers

(2016) Andrew L. Coveler et al.   INVESTIGATIONAL NEW DRUGS

Mesothelin Immunotherapy for Cancer: Ready for Prime Time?

(2016) Raffit Hassan et al.   JOURNAL OF CLINICAL ONCOLOGY

Antibody–drug conjugates for cancer therapy

(2016) Anish Thomas et al.   LANCET ONCOLOGY

Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates

(2016) Heather Donaghy   mAbs

Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer

(2016) C. D. Weekes et al.   MOLECULAR CANCER THERAPEUTICS

ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope

(2016) A. C. Phillips et al.   MOLECULAR CANCER THERAPEUTICS

Development of a Novel Antibody–Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1

(2016) Lawrence J. Thomas et al.   MOLECULAR CANCER THERAPEUTICS

The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer

(2016) M. Mattie et al.   MOLECULAR CANCER THERAPEUTICS

Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting SLITRK6 , a New Urothelial Cancer Biomarker

(2016) Kendall Morrison et al.   MOLECULAR CANCER THERAPEUTICS

Drugs and Drug Candidates from Marine Sources: An Assessment of the Current “State of Play”

(2016) David Newman et al.   PLANTA MEDICA

The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity

(2016) Michal Wieczorek et al.   Science Translational Medicine

Electrolytic Macrocyclizations: Scalable Synthesis of a Diazonamide-Based Drug Development Candidate

(2015) Hui Ding et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Effect of Attachment Site on Stability of Cleavable Antibody Drug Conjugates

(2015) Magdalena Dorywalska et al.   BIOCONJUGATE CHEMISTRY

Abstract 2480: MI130004, a new antibody-drug conjugate, induces strong, long-lasting antitumor effect in HER2 expressing breast tumor models

(2015) Pablo M. Aviles et al.   CANCER RESEARCH

Abstract 1693: ASN004, a novel 5T4-targeted Dolaflexin™ antibody drug conjugate, causes complete regression in multiple solid tumor models

(2015) Roger A. Smith et al.   CANCER RESEARCH

ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment

(2015) L. E. Lamberts et al.   CLINICAL CANCER RESEARCH

Antibody-drug conjugates: Intellectual property considerations

(2015) Ulrich Storz   mAbs

Abstract A147: MI130004, a new ADC with a payload of marine origin shows outstanding activity against HER2-expressing tumors

(2015) Pablo Aviles et al.   MOLECULAR CANCER THERAPEUTICS

AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML

(2015) D. S. Pereira et al.   MOLECULAR CANCER THERAPEUTICS

High Turnover of Tissue Factor Enables Efficient Intracellular Delivery of Antibody-Drug Conjugates

(2015) B. E. C. G. de Goeij et al.   MOLECULAR CANCER THERAPEUTICS

Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma

(2015) Michael Roth et al.   PEDIATRIC BLOOD & CANCER

A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies

(2015) S Y Kim et al.   Blood Cancer Journal

Abstract CT233: A first-in-human phase I study of the safety and pharmacokinetic (PK) activity of DEDN6526A, an anti-endothelin B receptor (ETBR) antibody-drug conjugate (ADC), in patients with metastatic or unresectable melanoma

(2015) Jeffrey R. Infante et al.   CANCER RESEARCH

Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy

(2015) Magdalena Dorywalska et al.   PLoS One

A Priori Prediction of Tumor Payload Concentrations: Preclinical Case Study with an Auristatin-Based Anti-5T4 Antibody-Drug Conjugate

(2014) Dhaval K. Shah et al.   AAPS Journal

Engineering more efficacious antibody therapy for myeloma

(2014) F. van Rhee   BLOOD

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma

(2014) Y.-T. Tai et al.   BLOOD

502 MI130004, an antibody–drug conjugate including a novel payload of marine origin: Evidences of in vivo activity

(2014) P.M. Aviles et al.   EUROPEAN JOURNAL OF CANCER

Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications

(2014) Andreas Maderna et al.   JOURNAL OF MEDICINAL CHEMISTRY

Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development

(2014) David Newman et al.   Marine Drugs

SGN-LIV1A: A Novel Antibody-Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer

(2014) D. Sussman et al.   MOLECULAR CANCER THERAPEUTICS

An Antibody-Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors

(2013) E. C. W. Breij et al.   CANCER RESEARCH

Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates

(2013) Pavel Strop et al.   CHEMISTRY & BIOLOGY

Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody–drug conjugates

(2012) Diego A. Gianolio et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

(2012) Peter D Senter et al.   NATURE BIOTECHNOLOGY

Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody–Drug Conjugates in Rats

(2011) C. Andrew Boswell et al.   BIOCONJUGATE CHEMISTRY

Antineoplastic Agents. 592. Highly Effective Cancer Cell Growth Inhibitory Structural Modifications of Dolastatin 10

(2011) George R. Pettit et al.   JOURNAL OF NATURAL PRODUCTS

In Vitro and In Vivo Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-Conjugated Antibody to Prostate-Specific Membrane Antigen

(2011) X. Wang et al.   MOLECULAR CANCER THERAPEUTICS

Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin

(2009) G. Kuznetsov et al.   MOLECULAR CANCER THERAPEUTICS